## **CLAIMS**

- 1. Pharmaceutical composition in the form of an aqueous solution or powder for the nasal administration of piribedil, characterised in that it comprises:
  - piribedil or a pharmaceutically acceptable salt thereof,
  - optionally a cyclodextrin,
  - one or more pharmaceutically acceptable excipients.
- 2. Pharmaceutical composition according to claim 1, characterised in that the piribedil is in the form of the base.
- 3. Pharmaceutical composition according to either claim 1 or claim 2, characterised in that the cyclodextrin is a partially methylated β-cyclodextrin.
- 10  $\underline{4}$ . Pharmaceutical composition according to claim 3, characterised in that the cyclodextrin is a  $\beta$ -cyclodextrin wherein the degree of substitution by methyl groups is around 1.7.
  - 5. Pharmaceutical composition according to any one of claims 1 to 4, characterised in that, for a final aqueous solution of 10 ml, the amount of piribedil is from 10 to 500 mg for an amount of cyclodextrin of from 75 to 3750 mg.
- 6. Pharmaceutical composition according to any one of claims 1 to 4, characterised in that, when the composition is in powder form, the amount of piribedil is from 0.1 mg to 20 mg for an amount of cyclodextrin of from 7.5 to 75 mg.

5